2011-07-01 Jiangsu Wuzhong (600200) Phase III clinical trial of new anti-cancer drug started
Yesterday, Jiangsu Wuzhong independently developed a national first-class biological anti-cancer new drug "recombinant" The Phase III clinical trial of "Human Endostatin Injection" has been launched, indicating that the research and development of this new drug has made phased progress. According to Chairman Zhao Weiwei, it has taken 10 years from the development of the new anti-cancer drug that has entered Phase III clinical trials to obtaining the Phase III drug clinical trial approval from SFDA, and about 250 million yuan has been invested. After several months of screening, demonstration and implementation, the product officially entered clinical trials. This process is estimated to take about 2 years, and then the new drug certificate and production approval can be applied for sales. At the same time, the four phases of the product will be carried out. Phase 1 clinical trial work. The production of a self-developed new drug has its own process and cycle, and it is not something that the market imagines will happen overnight.
As for the mechanism and advantages of this new anti-cancer drug, Zhao Weiwei told reporters that the drug achieves its therapeutic purpose by inhibiting tumor angiogenesis and blocking the nutrient supply to cancer cells. First, the drug is broad-spectrum. If other indications are subsequently developed, it can be adapted to patients with various cancers and has market potential. Second, phase II clinical trials have proven that the drug produces almost no antibodies and has accurate efficacy. The cancer lesions in the trial cases have been significantly reduced; thirdly, the company's recent invention patent for "Recombinant Protein Extraction and Purification Method" will significantly reduce drug costs. At present, this new drug has been included in China's major new drug creation science and technology projects and Jiangsu Province's major scientific and technological achievements transformation projects, and the product has obvious competitive advantages.
Source: Wu Yun, author of Shanghai Securities News